100 products were found matching "K04521"!

The beta-site amyloid precursor protein cleaving enzyme-1 (BACE-1) initiates the generation of amyloid-beta (Abeta), and the amyloid cascade leading to amyloid plaque deposition, neurodegeneration, and dementia in Alzheimer's disease (AD). Clinical failures of anti-Abeta therapies in dementia stages suggest that...

The beta-site amyloid precursor protein cleaving enzyme-1 (BACE-1) initiates the generation of amyloid-beta (Abeta), and the amyloid cascade leading to amyloid plaque deposition, neurodegeneration, and dementia in Alzheimer's disease (AD). Clinical failures of anti-Abeta therapies in dementia stages suggest that...

The beta-site amyloid precursor protein cleaving enzyme-1 (BACE-1) initiates the generation of amyloid-beta (Abeta), and the amyloid cascade leading to amyloid plaque deposition, neurodegeneration, and dementia in Alzheimer's disease (AD). Clinical failures of anti-Abeta therapies in dementia stages suggest that...

BACE-1 (beta-site APP cleaving enzyme-1) is an aspartic protease and an integral membrane protein . It is the major beta secretase, and together with the gamma secretase, is responsible for generating the amyloid beta peptide (A beta ) from the amyloid precursor protein (APP) Protein function: Responsible for the...

beta-Secretase inhibitor IV is an inhibitor of beta-site amyloid protein cleaving enzymes (BACE/beta-secretase) 1 and 2 (IC50s = 15 and 230 nM for human BACE1 and 2, respectively). It has >500-fold selectivity for BACE1 and 2 over the aspartyl proteases renin and cathepsin D. beta-Secretase inhibitor IV inhibits...

LY2886721 selectively inhibits the beta-site amyloid protein cleaving enzyme (BACE) (IC50 = 20 nM for recombinant hBACE1). BACE performs the first cleavage step in the Abeta cascade, thus, its inhibition by LY2886721 decreases production of all forms of the Abeta peptide. A Phase II clinical study for the use of...

Auraptene is a coumarin derived from citrus plants that bears a geranyloxyl moiety at its C-7. It has anti-inflammatory, anti-carcinogenic, anti-bacterial, neuroprotective, and hepatoprotective activities. It inhibits leukocyte activation and induces phase II enzymes during the initiation phase of carcinogenesis....

Accumulation of the beta-amyloid (Abeta) peptide in the brain is implicated as the primary cause of neurodegeneration and progression of Alzheimer's disease. Abeta is derived from sequential proteolytic cleavage of the amyloid precursor protein (APP) by beta-secretase (BACE) and gamma-secretase. LY2811376 is a...

Verubecestat is an inhibitor of beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) and BACE2 (Kis = 2.2 and 0.38 nM, respectively). It has a high selectivity for BACE1 and BACE2 over closely related aspartyl proteases, including cathepsin D. Formulations containing verubecestat profoundly lower levels of...

Mca-SEVNLDAEFR-K(Dnp)-RR-NH2 is a fluorogenic substrate for beta-secretase (BACE). Upon cleavage by BACE, 7-methoxycoumarin-4-acetyl (Mca) is released and its fluorescence can be used to quantify BACE activity. Mca displays excitation/emission maxima of 328/420 nm, respectively.Formal Name:...

Protein function: Responsible for the proteolytic processing of the amyloid precursor protein (APP). Cleaves at the N-terminus of the A-beta peptide sequence, between residues 671 and 672 of APP, leads to the generation and extracellular release of beta-cleaved soluble APP, and a corresponding cell-associated...

Bace1 (beta-secretase 1) is an aspartic protease that is involved in the processing of the Amyloid precursor protein (APP). Cleavage of APP by BACE1 followed by gamma-secretase results in beta-amyloid peptide production, which ultimately leads toxic Abeta accumulation. In Alzheimer's disease (AD), it has been widely...